$3.2m · Pre-Seed · Healthtech · Lisbon, Portugal
Octo Health has raised $3.2m in pre-seed funding led by 3xP Global. The company said the capital will support product development, including wearable integrations and automated access to medical records, as it opens its consumer health platform in the US.
Turning scattered records into a health timeline
Founded in 2023 by CEO Catarina Kemper, Octo Health brings medical records, lab results, medications, symptoms, wearable data and biomarker testing into one longitudinal view. The company positions the product as a way for consumers to spot changes over time and prepare better questions for clinicians, rather than as a diagnostic service or a replacement for medical care.
Its Complete product measures more than 115 biomarkers from blood and urine samples. Octo Health says results are returned within five business days, with testing supported by more than 2,200 partner lab locations in the US and Portugal. Members can also upload existing records and control time-limited sharing with doctors, according to its product and mission page.
The retention question is bigger than the test
The commercial challenge is turning an episodic lab purchase into an ongoing relationship. Octo Health offers testing from $149 and a Core membership from $9 per month, but the recurring value depends on the timeline becoming more useful as records, repeat tests and wearable signals accumulate. Wearable integrations and automated record access therefore matter beyond convenience: they can reduce the manual work required to keep the product current.
That creates a different proposition from a one-off wellness report. A persistent record can make switching harder and give members a reason to return between annual tests, but only if Octo Health explains changes clearly without crossing into unsupported clinical claims. The company's terms say users can delete their record, making trust and data controls part of the product rather than a compliance footnote.
A US-first launch from Lisbon
Octo Health developed its platform in Europe, and its team works between Lisbon and New York. The US beta gives the company access to a large direct-pay preventive-health market and an existing national lab network, while its Lisbon base keeps the business connected to its European roots.
The round now funds the infrastructure around that launch: connecting more data sources, reducing record fragmentation and making a longitudinal view useful enough to sustain membership after the first test.
